Literature DB >> 22608797

Greater percent-free testosterone is associated with high-grade prostate cancer in men undergoing prostate biopsy.

Simone Albisinni1, Cosimo De Nunzio, Andrea Tubaro, William T Barry, Lionel L Banez, Stephen J Freedland.   

Abstract

OBJECTIVE: To analyze the serum androgen concentrations in men who underwent an initial prostate biopsy, focusing on the percent-free testosterone (%FT) as a predictor of low- and high-grade prostate cancer (PCa). Most studies have suggested that the absolute serum testosterone and free testosterone levels are not related to PCa risk. However, to date, the concurrent effect of free and total testosterone levels has not been evaluated. In particular, the association of the %FT (free testosterone/total testosterone) with PCa risk has not been explored.
METHODS: From 2006 to 2010, we collected data on 812 white Italian men with no history of PCa who underwent 12-core biopsy. The testosterone, free testosterone, and %FT (free testosterone/total testosterone) were examined as predictors of low-grade (Gleason score of ≤ 6) and high-grade (Gleason score ≥ 7) PCa using crude and adjusted multinomial logistic regression analysis.
RESULTS: On multivariate analysis, testosterone (P ≥ .11) and free testosterone (P ≥ .45) were not significantly associated with low- or high-grade PCa. A greater %FT level significantly predicted high-grade PCa on both crude (P = .01) and multivariate (P = .02) analysis but not low-grade PCa (P ≥ .38). When examined in tertiles, men in the greatest %FT tertile had a significant twofold increased risk of high-grade PCa (odds ratio 2.04, 95% confidence interval 1.23-3.37, P = .005).
CONCLUSION: In white Italian men, a greater %FT level was associated with an increased risk of high-grade PCa on initial prostate biopsy. These findings suggest that a high %FT level, rather than the absolute androgen levels, might be associated with high-grade PCa. Additional studies are needed to confirm our findings.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22608797     DOI: 10.1016/j.urology.2012.01.068

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  6 in total

1.  Preoperative Plasma Levels of Total Testosterone Associated with High Grade Pathology-Detected Prostate Cancer: Preliminary Results of a Prospective Study in a Contemporary Cohort of Patients.

Authors:  Antonio B Porcaro; Nicolò De Luyk; Paolo Corsi; Marco Sebben; Alessandro Tafuri; Giovanni Cacciamani; Davide De Marchi; Irene Tamanini; Davide Inverardi; Matteo Brunelli; Maria A Cerruto; Gian L Salvagno; Gian C Guidi; Walter Artibani
Journal:  Curr Urol       Date:  2017-05-30

2.  Changes in the levels of testosterone profile over time in relation to clinical parameters in a cohort of patients with prostate cancer managed by active surveillance.

Authors:  Ahmed S Zakaria; Alice Dragomir; Wassim Kassouf; Simon Tanguay; Armen Aprikian
Journal:  World J Urol       Date:  2018-03-20       Impact factor: 4.226

Review 3.  DNA damage response and prostate cancer: defects, regulation and therapeutic implications.

Authors:  S Karanika; T Karantanos; L Li; P G Corn; T C Thompson
Journal:  Oncogene       Date:  2014-08-18       Impact factor: 9.867

4.  A novel model to predict positive prostate biopsy based on serum androgen level.

Authors:  Takeshi Ujike; Motohide Uemura; Atsunari Kawashima; Akira Nagahara; Kazutoshi Fujita; Yasushi Miyagawa; Norio Nonomura
Journal:  Endocr Relat Cancer       Date:  2017-10-18       Impact factor: 5.678

5.  Low levels of serum testosterone in middle-aged men impact pathological features of prostate cancer.

Authors:  Elton Llukani; Benjamin F Katz; Ilir Agalliu; Andrew Lightfoot; Sue-Jean S Yu; Martin Kathrins; Ziho Lee; Yu-Kai Su; Kelly Monahan Agnew; Alice McGill; Daniel D Eun; David I Lee
Journal:  Prostate Int       Date:  2017-01-12

6.  Genetics of Sex Hormone-Binding Globulin and Testosterone Levels in Fertile and Infertile Men of Reproductive Age.

Authors:  Marina Grigorova; Margus Punab; Olev Poolamets; Mart Adler; Vladimir Vihljajev; Maris Laan
Journal:  J Endocr Soc       Date:  2017-04-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.